Dashed lines are 95% confidence band around the curve.
Outcome expected at each level of symptom is shown. GAF indicates Global Assessment of Functioning; GAF-F, Global Assessment of Functional Performance; GAS, Global Assessment of Symptoms; and SADS, Schedule for Affective Disorders and Schizophrenia.
eFigure 1. Predictions of 3 nosologic models regarding relationships between nonaffective psychosis ratio and outcome
eFigure 2. Distributions of predictors
eMethods. Additional methodologic considerations
eTable. Comparison of nonlinear regression (LOESS) to linear regression
Kotov R, Leong SH, Mojtabai R, Erlanger ACE, Fochtmann LJ, Constantino E, Carlson GA, Bromet EJ. Boundaries of Schizoaffective DisorderRevisiting Kraepelin. JAMA Psychiatry. 2013;70(12):1276-1286. doi:10.1001/jamapsychiatry.2013.2350
Established nosology identifies schizoaffective disorder as a distinct category with boundaries separating it from mood disorders with psychosis and from schizophrenia. Alternative models argue for a single boundary distinguishing mood disorders with psychosis from schizophrenia (kraepelinian dichotomy) or a continuous spectrum from affective to nonaffective psychosis.
To identify natural boundaries within psychotic disorders by evaluating associations between symptom course and long-term outcome.
Design, Setting, and Participants
The Suffolk County Mental Health Project cohort consists of first-admission patients with psychosis recruited from all inpatient units of Suffolk County, New York (72% response rate). In an inception cohort design, participants were monitored closely for 4 years after admission, and their symptom course was charted for 526 individuals; 10-year outcome was obtained for 413.
Main Outcomes and Measures
Global Assessment of Functioning (GAF) and other consensus ratings of study psychiatrists.
We used nonlinear modeling (locally weighted scatterplot smoothing and spline regression) to examine links between 4-year symptom variables (ratio of nonaffective psychosis to mood disturbance, duration of mania/hypomania, depression, and psychosis) and 10-year outcomes. Nonaffective psychosis ratio exhibited a sharp discontinuity—10 days or more of psychosis outside mood episodes predicted an 11-point decrement in GAF—consistent with the kraepelinian dichotomy. Duration of mania/hypomania showed 2 discontinuities demarcating 3 groups: mania absent, episodic mania, and chronic mania (manic/hypomanic >1 year). The episodic group had a better outcome compared with the mania absent and chronic mania groups (12-point and 8-point difference on GAF). Duration of depression and psychosis had linear associations with worse outcome.
Conclusions and Relevance
Our data support the kraepelinian dichotomy, although the study requires replication. A boundary between schizoaffective disorder and schizophrenia was not observed, which casts further doubt on schizoaffective diagnosis. Co-occurring schizophrenia and mood disorder may be better coded as separate diagnoses, an approach that could simplify diagnosis, improve its reliability, and align it with the natural taxonomy.
The delineation of schizophrenia (dementia praecox) and psychotic mood disorders (manic-depressive insanity) as 2 distinct entities was one of Emil Kraepelin’s seminal contributions to nosology.1 More than 100 years later, this kraepelinian dichotomy remains highly influential.2 However, some patients exhibit features of both schizophrenia and psychotic mood disorders, which led Kasanin3 to propose a new category labeled schizoaffective disorder. Conceptualization of this condition evolved across editions of the DSM from a subtype of schizophrenia to a distinct disorder. DSM-IV4 defines it as (A) co-occurrence of schizophrenia symptoms and mood episodes, (B) psychosis present for at least 2 weeks in the absence of mood symptoms, and (C) mood episodes present for a substantial portion of illness duration. Thus, DSM-IV elaborates on the kraepelinian dichotomy by adding an intermediate condition, with criterion B defining its boundary with psychotic mood disorder and criterion C with schizophrenia. The key to classifying these disorders is the ratio of nonaffective psychosis to mood disturbance: in psychotic mood disorder, nonaffective psychosis is absent; in schizoaffective disorder, both nonaffective psychosis and mood episodes are prominent; and in schizophrenia, nonaffective psychosis predominates. However, some have argued that these boundaries are artificial and that psychotic disorders fall along a continuous spectrum that ranges from psychotic mood disorder to schizophrenia.5,6
These conflicting accounts inspired a substantial body of literature that evaluated the validity of schizoaffective disorder using several basic approaches. Investigations of phenomenology found support for the continuum model,7 the kraepelinian 2-disorders model,8,9 and the DSM-IV 3-disorders model.10 Studies of neurobiological and cognitive functioning, as well as family and genetic research, reported evidence favoring the continuum7,11 and 3-disorders12- 14 models. Longitudinal studies of illness course produced the most support for the continuum15,16 and 2-disorders8,17- 20 models. Thus, to date, the literature is too conflicting to offer firm recommendations for nosology. Some of these inconsistencies likely result from changes in schizoaffective diagnosis, which was defined more broadly by earlier diagnostic manuals.
Among diagnostic validators, illness course is of particular interest. Indeed, it was most central to Kraepelin’s work because he sought to develop diagnoses that would be prognostic of future symptoms and functioning (ie, global outcome).2 Unfortunately, existing longitudinal studies were not designed to answer questions about the natural organization of psychotic disorders. They typically compared outcomes among diagnostic groups: schizophrenia, schizoaffective disorder, and psychotic mood disorder, but such analyses cannot distinguish gradual differences (ie, a continuum) from qualitative changes (ie, natural boundaries). Indeed, in many studies15,16 outcome of schizoaffective disorder fell between that of schizophrenia and psychotic mood disorder, which is consistent with both the continuum and 3-disorders models.
Kendell and Brockington21 proposed a solution to this problem. They examined associations between the spectrum ranging from typical psychotic mood disorder to typical schizophrenia and continuous outcome measures. Their hypothesis was that a natural boundary would manifest as a significant drop in the outcome at some point along the spectrum, whereas a continuum would result in a linear decline. Kendell and Brockington found no evidence of a boundary, but their study was underpowered and analyses were limited to visual inspection of graphs.22 The latter shortcoming might explain why this technique has not been widely adopted. More recent developments in statistical methods23 make it possible to test such data for nonlinearity rigorously.
The aim of the present study was to test for the existence of natural boundaries in psychotic disorders using modern statistical methods. We analyzed detailed symptom course data from an epidemiologic cohort of inpatients with psychosis monitored prospectively for 10 years after their first hospitalization. In particular, we examined links between nonaffective psychosis ratio during the first 4 years of the study and outcomes at year 10. The continuum model predicts a linear association, the kraepelinian model predicts a single boundary between psychotic mood disorder and the schizophrenia spectrum, and the DSM-IV model predicts 2 boundaries, one between psychotic mood disorder and schizoaffective disorder and another between schizoaffective disorder and schizophrenia (Supplement [eFigure 1]). In the latter 2 models, differences are expected between groups (eg, low nonaffective psychosis and high nonaffective psychosis), but no association is predicted between nonaffective psychosis and outcome within groups. We constructed statistical models to test these hypotheses. We also used this method to explore natural boundaries within depression and mania.
Data for this study came from the Suffolk County Mental Health Project, an epidemiologic study of first-admission psychosis.24- 26 Patients were recruited from the 12 psychiatric inpatient units of Suffolk County, New York, between October 1989 and December 1995. Inclusion criteria were first admission, either current or within 6 months; clinical evidence of psychosis; age 15 to 60 years; IQ higher than 70; proficiency with English; and no apparent general medical etiology. The study was approved annually by the institutional review boards of Stony Brook University and the participating hospitals. Treating physicians determined participants’ capacity to provide consent. Written consent was obtained from adults and from parents of patients younger than 18 years.
We initially interviewed 675 participants (72% of referrals); 628 of them met the eligibility criteria. By the 4-year point, 10 participants had died, 29 were untraceable, 41 refused further participation, and 22 provided insufficient information about symptom course; the remaining 526 participants (83.8%) constituted the course sample. Of them, by the 10-year assessment, 27 had died, 28 were untraceable, 41 refused further participation, and 17 provided insufficient outcome information; the remaining 413 participants (78.5%) compose the outcome sample. These samples were very similar to each other and to the total cohort on the study variables (Table 1). The only significant differences between the course sample and the rest of the cohort (n = 102) were slightly younger age (P = .008) and lower prevalence of other psychoses in the sample (P = .044). The only significant difference between the outcome sample and the rest of the course sample (n = 113) was the slight overrepresentation of patients with low parental socioeconomic status in the former (P = 008).
Face-to-face assessments were conducted by master’s level mental health professionals at baseline, 6-month, 2-year, 4-year, and 10-year follow-up; telephone interviews were performed every 3 months until the 2-year wave and every 6 months until the 4-year wave. Interviewers were blinded to study diagnoses. Medical records and interviews with significant others were also obtained at each major assessment. These detailed data allowed raters to chart symptom course between baseline and year 4. At least half of the interval was documented for everyone in the course sample; 91.7% of them had at least 3.5 years of follow-up data.
Symptom documentation included start and end dates of psychotic, depressive, and manic episodes, each rated separately and defined according to DSM-IV criteria except for duration, which we did not require. Episodes were scored as (1) percentage of the observed interval psychotic, (2) percentage of patients depressed, and (3) percentage of patients manic (including hypomania). Of particular interest was the nonaffective psychosis ratio, scored as percentage of illness psychotic and not in mood episode (illness was defined as mood or psychotic episode), because this ratio defines the diagnostic boundaries of schizoaffective disorder in DSM-IV (especially criterion C).
Overall outcome is particularly relevant to validation of psychotic disorders.1,15,17,18 We examined 3 measures targeting its different aspects: Global Assessment of Symptoms (GAS) indicated overall symptom severity in the best month between the 4-year and 10-year interviews, Global Assessment of Functional Performance (GAF-F) indicated overall social and occupational functioning in the best month between 4-year and 10-year interviews, and Global Assessment of Functioning (GAF) was rated for the best month of the year before the 10-year interview considering both symptoms and functioning. Each measure was rated on a 0 to 90 scale (with 10 anchors specific to that rating) according to the DSM-III-R version of GAF, which was standard at the start of this study. To ensure that results were not influenced by format, we also evaluated the overall rating of psychosocial functioning from the Schedule for Affective Disorders and Schizophrenia (SADS),27 scored as 1, marked chronic condition; 2, moderate chronic condition; 3, mild chronic condition; and 4, complete return to highest functioning. These ratings were made by consensus of study psychiatrists (including L.J.F., E.C., and G.A.C.). Interrater reliability of consensus scores could not be assessed, but reliability of the individual raters was excellent, ranging intraclass r = 0.90-0.94 across outcomes.
Primary DSM-IV diagnosis was formulated at the 2-year point by consensus of 4 or more psychiatrists (including L.J.F. and G.A.C.) using all available information, including Structured Diagnostic Interview for DSM-IV28 with participants, medical records, and significant others.26 Diagnoses were grouped into 5 categories: schizophrenia/schizophreniform, schizoaffective, bipolar with psychosis, depression with psychosis, and other psychoses (eg, psychosis not otherwise specified and substance-induced psychosis). In assigning schizoaffective disorder diagnosis, psychiatrists interpreted criterion C (substantial portion) as requiring mood disturbance to be present for more than 30% of illness duration.
Demographic characteristics were also considered in analyses. They included age at baseline, sex, race, and socioeconomic status of the head of household.
First, we examined relationships between the 4 symptom course predictors and 4 outcomes using locally weighted scatterplot smoothing (LOESS),29,30 which uses weighted least squares to fit linear functions within a fixed neighborhood of each data point. If LOESS indicated nonlinearity of the association, we evaluated its exact form using spline regression.31- 33 Spline regression is a piecewise regression that fits polynomial functions onto segments of the predictor variable. In comparing fit of different spline models, we used 4 fit indices: the generalized cross-validation criterion, the Akaike information criterion, the Akaike information criterion corrected 1, and the Bayesian information criterion.34- 39 Analyses were performed using commercial software (SAS, version 9.2, with PROC LOESS and PROC NLIN; SAS Institute Inc).
The total duration of illness (psychotic or mood episodes) ranged from 2 days to 4 years. On average, participants were in an episode for a mean (SD) of 48.4% (39.0%) of the follow-up period. The distribution of psychosis duration was U-shaped (Supplement [eFigure 2]); 28.7% of participants were psychotic briefly (<5% of the follow-up period), 18.4% were psychotic constantly (>95%), and 52.9% were between these subgroups. The distribution of mania/hypomania was L-shaped: 58.6% had none in the interval, and others were spread across the entire spectrum of duration. Depression had a similar distribution, with 31.4% of the participants not depressed and others spread across the entire spectrum. The nonaffective psychosis ratio was U-shaped: 51.3% of the patients were psychotic only while in mood episodes, 20.7% had only nonaffective psychosis, and 28.0% had psychosis both in and outside of mood episodes.
Ten-year outcomes ranged widely: GAF scores from 21 to 90, GAF-F from 30 to 90, and GAS from 25 to 90. Distributions were positively skewed with modes in the low 40s. On SADS, 35.2% of participants were rated marked; 20.0%, moderate; 15.2%, mild; and 29.5%, remitted (returned to highest functioning).
First, we examined linear associations between the 4 symptom course variables and the 4 outcomes by conducting multiple regression analyses, with the 4 predictors entering simultaneously and each outcome serving as the dependent variable in turn. The strongest predictor was psychosis duration (β = −0.34 to −0.40), followed by nonaffective psychosis (−0.21 to −0.31) and finally depression (−0.13 to −0.21); coefficients for mania were not significant (Table 2). Zero-order correlations are given in the Supplement (eMethods).
To test for nonlinearity of these associations, we estimated LOESS models and compared them with linear models. The LOESS smoothed scatterplots for each predictor outcome pair and took whatever shape summarized the data best. For psychosis and depression, LOESS showed no improvement over the linear model: change in fit was small and nonsignificant (Supplement [eTable]). For mania and nonaffective psychosis, LOESS was significantly superior across all outcomes, and the improvement in fit ranged from Akaike Information Criterion Corrected 1 of 6.69 (substantial) to 51.57 (very substantial). Consistent with the fit indices, LOESS curves for psychosis and depression were essentially linear (Figure 1). Mania curves had an initial rise that plateaued and then gradually returned to the starting level. Nonaffective psychosis curves showed an initial drop that soon leveled. An apparent discontinuity in nonaffective psychosis contradicted the continuum model and was most consistent with the kraepelinian model. However, more rigorous modeling was needed to understand the exact form of the nonlinearity.
We used spline regression to more precisely evaluate nonlinearity detected by LOESS for nonaffective psychosis and mania. Psychosis and depression were not considered further because their associations with outcomes were purely linear. Spline regression allowed us to specify basic shapes of the curves to test target models and likely alternatives (Supplement [eMethods]).
For nonaffective psychosis, the fit indices consistently supported the kraepelinian model across the outcomes (Table 3). The only exception was GAS, for which 3 indices favored the DSM-IV model, but the fit of the kraepelinian model was nearly identical and superior on the Bayesian Information Criterion—the most parsimonious index. We named the identified groups nonaffective psychosis absent and nonaffective psychosis present. The boundary between them was at 1.5% of nonaffective psychosis ratio, that is, 10 days of psychosis outside of mood episodes (Figure 2).
For mania, the fit indices consistently supported the 3-group model over all alternatives (Table 3). The only exception was SADS, for which 3 indices favored the 4-group model, but fit of the 3-group model was nearly identical and the Bayesian Information Criterion favored 3 groups. We named the 3 groups mania absent, episodic mania, and chronic mania. The boundaries between them were 0.8% (11 days) and 27.0% (394 days) manic (Figure 2). In the episodic group, elevated mood consisted primarily of mania (mean, 65.4% of time in episodes), with the rest being mixed state (23.5%) or hypomania (11.1%). In the chronic group, mania (35.0%), mixed state (37.3%), and hypomania (27.7%) were evenly represented. The selected spline models fit the data much better than LOESS, indicating further support for these specific types of nonlinearity.
Next, we examined concordance between empirical groups identified by spline regression and DSM-IV diagnoses. Because diagnoses were assigned at the 2-year point, we scored empirical groups from the first 2 years of course data using the aforementioned cutoffs (1.5% on nonaffective psychosis, and 0.8% and 27.0% on mania).
Overall, concordance between the empirical groups and DSM-IV diagnoses was high. Nearly all (88.6) participants with schizophrenia or schizoaffective disorder diagnosis were in the nonaffective psychosis present group (Table 4); those who were assigned to nonaffective psychosis absent either had nonaffective psychosis before the first hospitalization—including the 5 schizoaffective cases—or had prominent negative symptoms outside mood episodes. Almost all (97.3%) cases of psychotic mood disorders were in the nonaffective psychosis absent group; the remaining 2.7% had only brief periods of nonaffective psychosis and their mood symptoms were much more severe than psychotic symptoms, resulting in psychotic mood disorder diagnosis.
Of participants with bipolar disorder, 20.7% were in the chronic mania group. Others were in the episodic mania group, except for 4 patients who had mania only before the first hospitalization and thus were classified in the absent group. Approximately half (53.8%) of participants with schizoaffective disorder diagnosis were in the episodic or chronic group. Mania was rare in other disorders.
With regard to outcomes, nonaffective psychosis present had notably worse scores than nonaffective psychosis absent (Table 4). The differences were more than 10 points on GAF, GAF-F, and GAS, and one level on SADS (ie, between moderate and mild condition). Similar differences were observed between mania absent and episodic mania. In contrast, the chronic mania group was similar to mania absent on all outcomes. Outcomes for DSM-IV schizoaffective disorder were similar to those of nonaffective psychosis present, whereas outcomes for schizophrenia were slightly worse (4-5 points on GAF metric). Participants with bipolar disorder did about as well as the episodic mania group.
Using modern statistical techniques—LOESS and spline regression—we detected strong nonlinearity in the relationship between ratio of nonaffective psychosis to mood disturbance and later outcome in our first-admission cohort with psychotic disorders. Specifically, we observed a qualitative difference in outcome between cases in which psychosis is limited to mood episodes and cases in which at least some psychosis is nonaffective. No other discontinuities emerged in analyses of nonaffective psychosis. These findings clearly support the kraepelinian dichotomy over the DSM-IV and continuum accounts. We found no evidence of a distinct schizoaffective disorder. Judged by outcome, this diagnosis appears to be a part of the schizophrenia spectrum. Other definitions of schizoaffective disorder that do not rely on nonaffective psychosis are possible and were not evaluated here. The analyses also revealed 2 distinct types of mania: episodic and chronic. In contrast, duration of psychosis and depression both had linear associations with outcomes and did not demarcate natural boundaries within psychotic disorders.
If replicated in other samples and with other validators, our results would have several implications for future editions of the DSM. Given the lack of validity of schizoaffective disorder diagnosis observed in this study and questionable support in the literature,7,40,41 continued use of this category is difficult to justify. Indeed, prior research7- 20 considered various validators: phenotypic, outcome, cognitive, neural, and genetic, and only 9 of 256 studies of this question concluded that schizoaffective disorder is a distinct condition.40 Our findings suggest that patients who currently are assigned a diagnosis of schizoaffective disorder would be better described as having schizophrenia (or schizophreniform disorder) with comorbid mood disorder. This nosologic change would reflect a growing recognition of the important role that mood comorbidities play in schizophrenia42- 44 and permit a flexible classification of psychotic illnesses without invoking an apparently arbitrary diagnostic category. Continuous ratings of severity for mood disorders and schizophrenia could further increase informational value of such a classification. Indeed, such ratings have been proposed for the DSM-5. With regard to schizoaffective diagnosis, the only significant revision considered for the DSM-5 is to make it explicitly a lifetime diagnosis,45 and this is how the disorder was approached in the present study. Our findings argue for reconsideration of schizoaffective disorder, but more research is needed.
In contrast, we found a clear discontinuity between schizophrenia spectrum disorders and psychotic mood disorder. In our data, even 10 days of nonaffective psychosis resulted in a qualitatively worse outcome. This is consistent with DSM-IV criteria for demarcating schizoaffective disorder and psychotic mood disorder (ie, 2 weeks of nonaffective psychosis). Bipolar disorder with psychosis also was clearly distinguished from other psychotic disorders, even with several days of manic symptoms forecasting qualitatively better outcomes. This finding is consistent with research10,16,17 indicating favorable outcomes for this disorder relative to other psychoses. In addition, we observed a discontinuity within the bipolar spectrum, suggesting existence of a chronic mania subtype defined by being manic for at least a year. This subtype has prognostic significance because it was associated with a distinctly worse outcome. Of note, all of these findings were consistent across several outcome measures, strengthening conclusions of the study. These measures reflect a single validator—global outcome—and are not independent replications, but they helped to ensure that the present results are not due to characteristics of a particular rating scale.
We did not hypothesize the chronic mania group a priori, and it requires confirmation, but this finding aligns well with the extant literature. Chronic mania was recognized as a distinct category in the 19th century.46 More recently, it has been operationalized as a manic episode lasting at least 2 years, and 6% to 13% of patients with bipolar I disorder fit this subtype.46 Of note, the 2-year definition of chronic mania was proposed based on a zone of rarity in distribution of episode length, but the zone ranged from 1 to 2 years.47 By the 1-year definition, prevalence of chronic mania is approximately 15%,48 which is comparable to the estimate in our cohort (20.7% of bipolar I disorder).
The observed empirical groups were defined by symptoms only. Nevertheless, both nonaffective psychosis and mania categories showed the anticipated convergence with DSM-IV diagnoses. There was only a handful of inconsistencies resulting from symptoms present before the first hospitalization or to highly prominent symptoms that received special weight in diagnostic decision making. In addition, mania groups included some patients with schizophrenia and other psychoses, which reflects the presence of comorbid mood disorders in these cases.
These empirical groupings had substantial predictive validity, forecasting more than 10-point differences in GAF among both nonaffective psychosis and mania groups years later. The DSM-IV diagnosis was somewhat more predictive, with schizophrenia outcome being 5 GAF points lower than the nonaffective psychosis present group. Schizophrenia diagnosis explicitly requires marked deterioration of functioning (criterion B), which likely explains why this group fared worse than the nonaffective psychosis present group. Altogether, it is remarkable that simple classification rules based solely on symptomatology were almost as predictive as full DSM-IV diagnosis.
The observed sharp distinction between no nonaffective psychosis and any nonaffective psychosis and the large effect it had on outcome suggests differences in etiologies of these groups. For instance, psychotic symptoms in schizophrenia spectrum disorders may result from neurodevelopmental pathologic factors, whereas psychosis in psychotic mood disorder may be induced by stress.49,50 These findings contradict the continuum view of psychotic disorders, but psychotic mood disorder and nonaffective psychosis may share some risk factors and pathophysiologic processes. Many such commonalities have been documented51,52 and may explain their substantial comorbidity.42- 44 In our sample, 57% of the nonaffective psychosis group experienced at least one mood episode. The degree of overlap versus distinction among these conditions can be further explicated by applying nonlinear modeling to other validators.
Our rejection of the 3-disorder model in favor of the kraepelinian dichotomy seems to be at odds with studies15,16 reporting better outcomes in schizoaffective disorder compared with schizophrenia. Importantly, schizoaffective disorder is defined only by symptom pattern and, unlike schizophrenia, does not require marked functional impairment or 6-month duration, which likely explains differences in outcome. Indeed, in our cohort, outcome of schizoaffective disorder was no different from the outcome of the rest of the nonaffective psychosis group. Quantitative distinctions among patients with psychotic disorders also must be recognized. We found that of all variables considered, duration of psychosis was the most important predictor of outcome. Clinicians need to remain vigilant to long-term disability associated with chronic psychosis.
Strengths of this investigation include a first-admission epidemiologic cohort that was followed long-term and a painstaking tracking of symptoms and functioning using interviews, informant reports, and medical records. Nevertheless, the present findings need to be considered against the study’s limitations. First, detailed documentation of symptoms was limited to 4 years and sometimes did not include illness onset. This investigation targeted a crucially important period of illness course, but close tracking of symptoms over a long term would provide a more definitive test of diagnostic boundaries. Second, validation of diagnostic distinctions was limited to long-term outcome. Kraepelin1,2 considered illness course the key consideration for diagnostic validity, but a comprehensive evaluation has to include other characteristics, such as genetic risk factors, neural substrates, and treatment response.53 This effort requires integration of findings from different research paradigms, and the present study is a step toward this goal. Third, the present report focused on global outcomes, as these have been the primary benchmarks for other longitudinal studies of schizoaffective disorder.15,17,18 We also collected fine-grained information and will investigate specific outcomes in subsequent studies. Fourth, each outcome was a single rating, and such variables tend to have low reliability. To ensure strong psychometric properties, the present ratings were made by consensus of research psychiatrists based on all available information. Fifth, consensus diagnosis was available at the 2-year rather than 4-year point, so we had to limit analyses comparing diagnoses and empirical groups to 2 years of symptom course. Sixth, we could not investigate treatment effects in this naturalistic study, and it is important to confirm present findings in randomized trials, controlling for treatment experiences. Finally, generalizability of the present results was limited by attrition. Fortunately, attrition during the 10-year study was modest and had little effect on study variables.
In conclusion, if replicated, our findings would provide clear support for the kraepelinian dichotomy, and this sharp boundary presents a significant challenge for the continuum view of psychotic disorders. Also, absence of the boundary between schizophrenia and schizoaffective disorder calls validity of the latter into question. Schizoaffective disorder was an early advance that recognized the co-occurrence of schizophrenia and mood disorders. It was an imperfect solution, however, and the present findings suggest that coding of comorbid schizophrenia (or schizophreniform disorder) and mood disorder as 2 separate diagnoses may serve the field better than the schizoaffective category. In fact, the DSM-IV already permits such coding, and this proposal would extend it to cases currently diagnosed as schizoaffective disorder. This change also would streamline differential diagnosis for psychotic disorders. Indeed, the reliability of schizoaffective disorder diagnosis is remarkably poor.26,54 Much of this difficulty stems from criterion C,54 which separates schizoaffective disorder from schizophrenia with comorbid mood disorder. Our results suggest that this distinction is superfluous, which may explain the associated unreliability. Thus, by abolishing the schizoaffective disorder category while maintaining the qualitative distinction between psychotic mood disorder and schizophrenia spectrum disorders, it may be possible to align the nosology with the natural taxonomy of psychoses, simplify diagnosis, and improve its reliability. This contention requires verification in other samples and with a variety of validators.
Submitted for Publication: November 15, 2012; final revision received February 6, 2103; accepted April 2, 2013.
Corresponding Author: Roman Kotov, PhD, Department of Psychiatry and Behavioral Science, Putnam Hall-South Campus, Stony Brook University, Stony Brook, NY 11794 (email@example.com).
Published Online: October 2, 2013. doi:10.1001/jamapsychiatry.2013.2350.
Author Contributions: Dr Kotov takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Kotov, Mojtabai, Carlson.
Acquisition of data: Kotov, Fochtmann, Constantino, Bromet.
Analysis and interpretation of data: Kotov, Leong, Mojtabai, Erlanger.
Drafting of the manuscript: Kotov, Leong, Erlanger, Bromet.
Critical revision of the manuscript for important intellectual content: Leong. Mojtabai, Erlanger, Fochtmann, Constantino, Carlson, Bromet.
Statistical analysis: Kotov, Leong.
Obtained funding: Kotov, Bromet.
Administrative, technical, and material support: Kotov, Erlanger.
Study supervision: Kotov, Erlanger, Bromet.
Conflict of Interest Disclosures: None reported.
Funding/Support: National Institutes of Health grant MH094398 to Dr Kotov and MH44801 to Dr Bromet.
Role of the Sponsor: The National Institutes of Health had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: Greg Perlman, PhD, Adam Gonzalez, PhD, and Camilo Ruggero, PhD, provided feedback on the manuscript. We thank the mental health professionals in Suffolk County, the project psychiatrists and staff, and most of all, the study participants and their families and friends. The project psychiatrists and staff received their usual salary support; no others were paid for their services.